Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 4 3Phase 3 3Phase 2 3

Status

Completed 37Terminated 13Withdrawn 4Unknown 3Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 46Neoplasms 43Multiple Myeloma 41Stomach Neoplasms 34Lung Neoplasms 32Ovarian Neoplasms 31Neoplasm Metastasis 31Leukemia, Myeloid, Acute 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Triple Negative Breast Neoplasms 25Recurrence 25Pancreatic Neoplasms 25Small Cell Lung Carcinoma 21Esophageal Neoplasms 21Brain Neoplasms 21Uterine Cervical Neoplasms 20Colonic Neoplasms 20Lymphoma, Large B-Cell, Diffuse 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

relugolix 2Megestrol Acetate 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Leiomyoma × Clear all
NCT07378098 2026-05-01

to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia

JW Pharmaceutical

Phase 3 Recruiting
254 enrolled

Leiomyoma, Menorrhagia

NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

NCT05862272 2025-08-06

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Sumitomo Pharma Switzerland GmbH

Phase 3 Recruiting
1,000 enrolled

Endometriosis, Leiomyoma, Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡